Propanc Biopharma Publishes Peer-Reviewed Research on PRP's Impact on Pancreatic Cancer Tumor Microenvironment
Key Insights
Propanc Biopharma (search) and research partners from Universities of Jaén and Granada published findings in Scientific Reports demonstrating PRP's multifaceted effects on pancreatic ductal adenocarcinoma (search)-associated fibroblasts and tumor microenvironment disruption.
The study highlights PRP as a promising adjunct therapeutic candidate capable of disrupting key interactions within the PDAC (search) tumor microenvironment, targeting cancer-associated fibroblasts (search) that drive tumor advancement and metastasis.
Propanc plans to initiate Phase 1b clinical trials in Q3 2026 for advanced solid tumor patients, with PDAC (search) as a target indication for subsequent Phase 2 studies.
Propanc Biopharma (search) has published peer-reviewed research demonstrating the potential of its lead candidate PRP to disrupt the tumor microenvironment in pancreatic ductal adenocarcinoma (search) (PDAC (search)), offering new insights into targeting one of the most lethal cancers. The findings, published in Scientific Reports from Nature publishers, represent a significant milestone in the company's clinical development program as it prepares for Phase 1b trials in 2026.
Breakthrough Research on Tumor Microenvironment Disruption
The collaborative study between Propanc Biopharma (search) and researchers from the Universities of Jaén and Granada focused on PRP's impact on pancreatic ductal adenocarcinoma (search)-associated fibroblasts. The research, titled "Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts," was published in the open-access journal Scientific Reports.
The study revealed that PRP exerts multifaceted effects specifically on cancer-associated fibroblasts (search) (CAFs (search)) and tumor cells. PDAC (search) is characterized by a dense fibrotic stroma containing a significant enriched population of CAFs, and the interplay between CAFs and tumor cells is crucial in driving tumor advancement and metastasis.
"Our findings demonstrate that PRP exerts multifaceted effects specifically over the CAFs (search) population and tumor cells. All together, these results highlight PRP as a promising adjunct therapeutic candidate capable of disrupting key interactions within the PDAC (search) TME," said Dr. Belén Toledo, PhD, joint lead researcher from the University of Jaén (search).
PRP's Unique Mechanism of Action
PRP consists of two bovine-derived pancreatic proenzymes, trypsinogen (search) and chymotrypsinogen (search), formulated in a synergistic 1:6 ratio and administered intravenously. The compound is hypothesized to target cancer stem cells (search) (CSCs) and modulate malignant cellular programs such as the epithelial to mesenchymal transition (EMT), a process linked to metastasis and drug resistance.
Key mechanistic findings from preclinical studies include suppression of metastatic processes, with PRP reducing angiogenesis and cell migration in pancreatic cancer (search) models while appearing to reverse EMT markers that contribute to invasiveness. Laboratory data suggest PRP enhances chemosensitivity, making resistant pancreatic tumor cells more responsive to standard chemotherapies and altering the tumor microenvironment, including reduced fibrosis and dampened TGF-β pathway (search) signaling.
In vivo studies in animal models showed significant reduction in pancreatic tumor weight, with greater than 85% growth inhibition at certain PRP doses versus controls. The U.S. Food and Drug Administration granted Orphan Drug Designation to PRP in 2017 for the treatment of pancreatic cancer (search), recognizing the severe unmet need and small patient population.
Clinical Development Timeline
Propanc CEO James Nathanielsz emphasized the significance of the published research: "After several years of research pioneered with our scientific researchers, we find ourselves publishing compelling scientific evidence that PRP has the potential to dramatically alter the way we perceive poor patients diagnosed with this killer disease."
The company plans to undertake its Phase 1b study in advanced cancer patients suffering from solid tumors in Q3 2026. "This pivotal study will determine our target dose for Phase 2 studies in which PDAC (search) is one of our target therapeutic indications. We look forward to advancing PRP into the clinic as soon as possible to help PDAC patients with such a poor survival prognosis," Nathanielsz stated.
Future clinical investigation is planned to validate the translational potential of PRP as an adjunct therapy for PDAC (search) patients who no longer respond to standard treatment regimens.
Addressing Critical Unmet Medical Need
Pancreatic cancer (search) remains one of the most lethal human malignancies, with median survival after diagnosis typically measured in months and five-year survival rates below 10%. Traditional therapies such as surgery, chemotherapy and radiation often fail to achieve durable remission, especially in metastatic or chemoresistant disease.
Despite recent advancements in clinical management, PDAC (search) remains one of the most aggressive and deadliest forms of cancer, projected to become the second leading cause of cancer-related deaths by 2030. PDAC is characterized by its late-stage diagnosis, limited treatment options, and poor prognosis.
Market Opportunity and Financial Position
The global pancreatic cancer (search) treatment market is forecast to grow from approximately USD 2.9 billion in 2024 to USD 5.8 billion by 2030, representing a compound annual growth rate of 12.3%. According to Propanc and external research estimates, the pancreatic cancer segment targeted by PRP is forecast to reach roughly $6.93 billion by 2030.
Combined with ovarian cancer (search), which is also a focus for PRP, the total addressable market over the coming decade has been cited in the $14-18 billion range. North America, particularly the United States, constitutes one of the largest revenue sectors in this market.
Propanc Biopharma (search) is a pre-revenue biotechnology company focused on early-stage clinical development. A recent IPO and Nasdaq listing raised approximately $4 million in gross proceeds, with Propanc positioning itself for clinical advancement of PRP and a recombinant follow-on candidate. The company has entered structural financing arrangements, including a potential $100 million private placement facility to fund further development.